| Blau syndrome initially manifested with hypercalcemia: a case report and literature review |
Poomrapee Tantikittipisut1, Rungroj Thangpong2,3, Phawin Kor-anantakul3,4, Wuttichart Kamolvisit3,4, Khomsak Srilanchakon5, Roongroj Manatpreeprem1,6, Kanya Suphapeetiporn2,3, Parichat Khaosut1,6 
|
1Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
2Division of Medical Genetics and Metabolism, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
3Excellence Center for Genomics and Precision Medicine, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand
4Center of Excellence for Medical Genomics, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
5Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
6Center of Excellence for Allergy and Clinical Immunology, Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand |
Address for correspondence:
Parichat Khaosut
Email: parichat.k@chula.ac.th
|
|
Received: September 25, 2025 Revised: December 21, 2025 Accepted: January 6, 2026 |
|
|
|
|
| Abstract |
|
Blau syndrome, a granulomatous autoinflammatory disease, is a rare condition that is typically characterized by a triad of polyarthritis, uveitis, and dermatitis. It is caused by either an autosomal dominantly inherited or a de novo pathogenic variant in the NOD2 gene. In this report, we present a case of an 11-month-old male with Blau syndrome who presented with calcitriol-mediated hypercalcemia at an early stage. Severe hypercalcemia was controlled by intravenous fluid therapy, diuretics, calcitonin and a short course of corticosteroids. Following resolution of the hypercalcemic episode, the patient gradually developed the full clinical spectrum of Blau syndrome, including symptoms of the classic triad, along with hepatosplenomegaly, lymphadenopathy, and bone marrow involvement. Trio-genome sequencing reported a de novo pathogenic heterozygous variant in the NOD2. Following the genetic testing result, corticosteroids and methotrexate were introduced to control the disease. This is the first reported case of Blau syndrome presenting with hypercalcemia as an initial manifestation, preceding the development of the classic triad of symptoms. This case underscores the importance of considering Blau syndrome in the differential diagnosis of early-onset hypercalcemia of unknown etiology. Molecular genetic testing should be pursued in such cases to facilitate accurate and timely diagnosis, enabling appropriate management. |
| Keywords:
Hypercalcemia; calcitriol ; Blau syndrome; Autoinflammatory disease; Granulomatous disease; NOD2 variant |
|
PDF Links
Full text via DOI
Download Citation
